Ist ARADIGM die neue Biotechnologiechance für uns????? - 500 Beiträge pro Seite

[bruzza]

Ich denke, hier habe wir einen Wert, der über alles verfügt, was eine Aktie braucht: Fundamental gut, da das Konzept stimmt und ein wenig Werbung durch den Aktionär hierzulande. Ist das eine Aktie, die sich lohnt? Ich meine, wer will schon Insulin über die Lungen aufnehmen? Ich glaube das ist ein Scheiß Wert, warum steigt, der denn so jut. Nur weit der Aktionär die Sache empfielt und daraufhin in Deutschland so ca. 10000 Stück gehandelt werden, kann dass den Kurs am Nasdaq nicht beeinflussen, wo 1,75 Mio gehandelt werden.
Aber die Geschichte mit Medikamenten, wie z. B Insulin über die Atemwege zu injezieren, ist eine super Sache und hat auf jeden Fall Zukunft!
Kann mir jemand sagen, wie das zustande kommt?
bruzza

[Kostolany4]

Aradigm is engaged in the development of advanced pulmonary drug delivery systems for the treatment of systemic
conditions as well as lung diseases. For the nine months ended 9/30/01, revenues rose 45% to $22.1 million. Net loss
before extraordinary item rose 16% to $28.8 million. Results reflect revenues derived from collaboration agreements with
Novo Nordisk A/S and GlaxoSmithKline, offset by increased R and D expenses related to the development of the AERx
System.
http://biz.yahoo.com/p/a/ardm.html

Novo Nordisk invests USD 20 million in Aradigm Corporation

HAYWARD, Calif. and COPENHAGEN, Denmark, Oct. 24 /PRNewswire/ -- Aradigm Corporation (Nasdaq: ARDM -
news) and Novo Nordisk A/S (NYSE: NVO - news) announced today that Novo Nordisk has made an investment of USD 20
million in Aradigm common stock. Under the terms of the investment, Aradigm sold approximately 5,665,723 shares of common
stock at USD 3.53 per share.

Aradigm and Novo Nordisk are currently in Phase 2 clinical trials with the AERx (R) insulin Diabetes Management System
(iDMS). Clinical results to date confirm that pulmonary drug delivery using the AERx (R) System is a reproducible method for
delivering insulin to the bloodstream that is comparable to subcutaneous administration.

``Aradigm and Novo Nordisk are jointly developing a product that offers a precise and flexible system for non-invasive insulin
delivery that we believe will become an important treatment option for people with diabetes,`` said Mads Krogsgaard Thomsen,
executive vice president and chief science officer at Novo Nordisk. ``We are pleased to have the opportunity to invest in our
partner Aradigm.``

As part of this agreement, Novo Nordisk will retain all of the Aradigm stock held by it for at least two years from the effective
date of this agreement, subject to certain conditions.

In a separate agreement, Aradigm and Novo Nordisk have decided that Novo Nordisk will assume the responsibility for
providing manufacturing capacity for all requirements beyond that produced in Aradigm`s recently completed Hayward,
California commercial scale manufacturing facility. This agreement creates an important limit on Aradigm`s requirement to invest
in additional manufacturing facilities to meet higher product volumes. There were no material changes in the other financial
arrangements between the companies. In addition, Novo Nordisk`s rights have been expanded to include full ability to produce
product using Aradigm`s proprietary technology at its production facilities.

``These agreements are a further demonstration of the confidence Novo Nordisk has in our program,`` stated Rick Thompson,
chairman, president and CEO of Aradigm. ``Our teams are very pleased with the safety and efficacy data generated to date as
we prepare for the initiation of Phase 3 trials.``

The agreement will not impact Novo Nordisk`s expectations for the financial result for 2001.

Novo Nordisk A/S is a focused healthcare company and the world leader in diabetes care. In addition, Novo Nordisk
manufactures and markets a variety of other pharmaceutical products. With headquarters in Denmark, Novo Nordisk employs
approximately 15,000 people in 68 countries and markets its products in 179 countries. Its B shares are listed on the stock
exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ``NVO``. For
further company information visit http://www.novonordisk.com.

Aradigm is working to improve the quality of life of patients by developing aerosol-based drug delivery alternatives to injectable therapeutics. The Company`s
advanced pulmonary delivery technologies provide leading pharmaceutical and biotechnology partners with effective drug delivery solutions. Aradigm`s technology
uses liquid drug formulations that are similar to the injectable forms and minimize the potential for safety concerns when delivered by the pulmonary route. Current
development programs focus on diabetes, pain management, and the pulmonary delivery of existing and emerging biotech therapeutics.

Based in Hayward, California, Aradigm is currently developing products for diabetes management with Novo Nordisk A/S, the world leader in insulin and
diabetes care, and breakthrough and acute pain management for GlaxoSmithKline, a world leader in oncology therapy and supportive care. In addition, Aradigm
has four additional partner-funded programs and a gene therapy effort funded through the National Institutes of Health. More information about Aradigm can be
found at www.aradigm.com. Investors may also request company information via email by directing inquiries to [e-mail].

Please note:

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including the timely
development, availability and acceptance of new products, the impact of competitive products and pricing, and the management of growth, as well as the other
risks detailed from time to time in Aradigm and Novo Nordisk`s Corporation`s Securities and Exchange Commission (SEC) Registration Statements, including the
companies Annual Reports on Form 10-K (Aradigm Corporation) and Form 20-F (Novo Nordisk) as amended.

http://biz.yahoo.com/prnews/011024/new055_1.html

[/b]
Das klingt in der Tat nicht so schlecht. Der Kurs ist seit 3 Tagen um 70% gestiegen. Das könnte tatsächlich
ein Push durch irgendeine Empfehlung gewesen sein.

[Sugar2000]

Warum sagst du dass es ein Scheißwert ist???
Ich meine ich kenne die Aktie erst seit 1 minute aber wenn die mit inhalierbarem Insulin Erfolge aufweisen können!
Ich persönlich glaube nicht an inhalierbares Insulin, da es nicht die Ziele erreicht! Es wird vom Körper abgestoßen!
Interessant finde ich in Sachen Diabetesforschung zwei andere Aktien!
1. Sangui (die forschen an einer Insulinpumpe mit Glukosesensor)
2. StemCells (Stammzellenunternehmen, aber nicht auf Basis embryonaler Stammzellen)

Gruß
Sugar

[bruzza]

Im Grunde is die Aktie nicht schlecht. Ich sebst besitze sie ja auch, aber die fundamenntalen daten und das Konzept rechtfertigen noch lange nicht den Anstieg der letzten Tage. Ich freue mich ja auch darüber, aber ich kann es mir nicht erklären. Der Aktionär, der Aradigm empfohlen hat, agiert in Deutschland. Diese Empfehlung kann den Kurs in den USA nicht so treiben. Und ein gutes Konzept reicht leider nicht immer. Was meinst Du spricht für und was gegen die Aktie? bruzza

[Sagini]

Nachdem der Wiederstand bei sechs Us-Dollar (etwa 6,7 Euro) nachhaltig überwunden und durch einen kurzen Rücksetzer bestätigt werden konnte,ist nun der Weg nach oben entgültig frei.Untermauert wird die positive Charttechnik durch eine fundamental gute Story. Das elektronische Verabreichungssystem AERx iDMS erfüllt alle Anforderungen einer modernen Insulintherapie.Die Aktie ist auf aktuellem Niveau (7,25)immer noch ein klarer Kauf.

Quelle: Der Aktionär